Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen.

We assessed the safety and immunogenicity of hepatitis B vaccination among 40 human immunodeficiency virus-infected patients with isolated positivity for antibodies to hepatitis B core antigen. No baseline factors were found to be predictive of an anamnestic response, which occurred in 32.5% of the patients. The overall response rate among patients without an anamnestic response was 74.0% after 3-6 vaccine doses.

[1]  C. Mengoli,et al.  Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. , 2009, Vaccine.

[2]  S. Grabar,et al.  Immunological Efficacy of a Three-Dose Schedule of Hepatitis A Vaccine in HIV-Infected Adults: HEPAVAC Study , 2008, Journal of acquired immune deficiency syndromes.

[3]  S. Alavian,et al.  Predicting response to HBV vaccination in people with positive anti-HBc but negative HBsAg and anti-HBs , 2008, Human vaccines.

[4]  J. Angel,et al.  CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Bruno,et al.  European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV‐infected adults , 2008, HIV medicine.

[6]  C. Leport,et al.  Occult hepatitis B in HIV-HCV coinfected patients , 2008, Scandinavian journal of infectious diseases.

[7]  M. Young,et al.  Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. , 2007, The Journal of infectious diseases.

[8]  P. Sax,et al.  Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. , 2005, The Journal of infectious diseases.

[9]  Giorgio Palù,et al.  Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.

[10]  M. Wallace,et al.  Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  D. Neau,et al.  Isolated antibodies against the core antigen of hepatitis B virus in HIV‐infected patients , 2004, HIV medicine.

[12]  A. Lechi,et al.  Isolated presence of antibody to hepatitis B core antigen in injection drug users: do they need to be vaccinated? , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Lang,et al.  Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. , 2000, Vaccine.

[14]  K. Meyer zum Büschenfelde,et al.  Kinetics of hepatitis B surface antigen–specific immune responses in acute and chronic hepatitis B or After HBs vaccination: Stimulation of the in vitro antibody response by interferon gamma , 1999, Hepatology.

[15]  B. McMahon,et al.  Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Rosman,et al.  Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. , 1997, The American journal of medicine.

[17]  I. Symington,et al.  Influence of smoking on immunological responses to hepatitis B vaccine. , 1994, Vaccine.

[18]  B. McMahon,et al.  Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. , 1992, Gastroenterology.